Legend Biotech Corporation (LEGN)

Etorro trading 970x250
Legend Biotech Corporation (LEGN) Logo

About Legend Biotech Corporation

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel cell therapies for oncology and other indications. Its lead product candidate, LCAR-B38M/JNJ-4528, is an autologous CAR-T cell therapy that targets the B-cell maturation antigen. The company is conducting multiple clinical trials to evaluate LCAR-B38M/JNJ-4528 as an earlier line of therapy for multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in Revlimid-refractory MM. It also has a broad portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, the company is developing an allogeneic CAR-T product candidate targeting CD20 for the treatment of NHL, which is currently in an investigator-initiated Phase 1 clinical trial in China. Further, it has various product candidates in early preclinical and clinical development for the treatment of solid tumors, as well as infectious diseases. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation. Address: 2101 Cottontail Lane, Somerset, NJ, United States, 08873

Legend Biotech Corporation News and around…

Latest news about Legend Biotech Corporation (LEGN) common stock and company :

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Interesting LEGN Put And Call Options For December 17th
08 Oct, 2021 FinancialContent

Investors in Legend Biotech Corp (LEGN) saw new options become available today, for the December 17th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 70 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
05 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
01 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

Legend Biotech to Host R&D Day on October 18, 2021
22 Sep, 2021 FinancialContent

Legend Biotech will host its first Research & Development Day on Monday, October 18, commencing at 10:00 a.m. (Eastern Time), at Andaz 5th Avenue.

Is Legend Biotech (NASDAQ:LEGN) Using Debt In A Risky Way?
21 Sep, 2021 Yahoo! Finance

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Stocks Showing Market Leadership: Legend Biotech Corp Earns 91 RS Rating
21 Sep, 2021 FinancialContent

Legend Biotech Corp sees its Relative Strength Rating reach the elite 90-plus level.

Week In Review: Everest Announces Two In-Licensings With Total Value Of $1 Billion
18 Sep, 2021 FinancialContent

Shanghai Everest Medicines in-licensed a BTK inhibitor for renal diseases from Suzhou Sinovent and SinoMab Bio in a $561 million deal. Shanghai Everest Medicines announced a $500 million two-part deal with Providence Therapeutics for mRNA products.

Stocks Showing Improving Market Leadership: Legend Biotech Corp Earns 81 RS Rating
16 Sep, 2021 FinancialContent

A Relative Strength Rating upgrade for Legend Biotech Corp shows improving technical performance.

IBD Rating Upgrades: Legend Biotech Corp Shows Improved Technical Strength
15 Sep, 2021 FinancialContent

Legend Biotech Corp shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Legend Biotech Begins Phase 1 Clinical Trial in the US to Evaluate Investigational Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma
13 Sep, 2021 FinancialContent

Legend Biotech has announced the start of a Phase 1 clinical trial in the US for an investigational treatment for relapsed/refractory T-cell lymphoma.

Legend Bio Starts US Trial of CD4 CAR-T Therapy for Lymphoma
13 Sep, 2021 FinancialContent

Nanjing Legend Biotech has started a US Phase 1 trial of its autologous CD4 CAR-T therapy for lymphoma. The trial will enroll adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL). LB1901 targets CD4, a surface membrane glycoprotein expressed in most TCL subtypes. Legend's lead candidate, cilta-cel, is a BCMA-targeted CAR-T for multiple myeloma that is under review for marketing approval in China, the US and EU. Legend partnered cilta-cel with Janssen Pharma. More details.... Stock Symbol: (NSDQ: LEGN) Share this with colleagues:

Here's Why Ziopharm Oncology Stock Is Up 18% This Week
10 Sep, 2021 FinancialContent

Recent insider stock purchases were more than a little encouraging.

Stock Upgrades: Legend Biotech Corp Shows Rising Relative Strength
08 Sep, 2021 FinancialContent

Legend Biotech Corp shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 84.

Stocks With Rising Relative Strength: Legend Biotech Corp
01 Sep, 2021 FinancialContent

A Relative Strength Rating upgrade for Legend Biotech Corp shows improving technical performance. Will it continue?

Legend Biotech to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference
30 Aug, 2021 FinancialContent

Legend Biotech (NASDAQ: LEGN) will participate in the 19th Annual Morgan Stanley Virtual Global Healthcare Conference on September 10 at 8:45 a.m. ET.

Stocks Showing Improved Relative Strength: Legend Biotech Corp
25 Aug, 2021 FinancialContent

A Relative Strength Rating upgrade for Legend Biotech Corp shows improving technical performance. Will it continue?

Legend Biotech Reports Second Quarter 2021 Financial Results and Recent Highlights
23 Aug, 2021 FinancialContent

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today reported its 2021 second quarter unaudited financial results.

The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs
23 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Should Legend Biotech (NASDAQ:LEGN) Be Disappointed With Their 32% Profit?
23 Jul, 2021 Yahoo! Finance

On average, over time, stock markets tend to rise higher. This makes investing attractive. But if when you choose to...

The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO
22 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay
21 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Highs On Tuesday
20 Jul, 2021 FinancialContent

On Tuesday morning, 54 companies achieved new highs for the year. Noteworthy Mentions: The largest company ...

Legend Biotech Corporation Sponsored ADR (LEGN) Stock Jumps 7.8%: Will It Continue to Soar?
20 Jul, 2021 Yahoo! Finance

Legend Biotech Corporation Sponsored ADR (LEGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
20 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Legend Biotech Corp Clears Technical Benchmark, Hitting 90-Plus RS Rating
20 Jul, 2021 FinancialContent

A Relative Strength Rating upgrade for Legend Biotech Corp shows improving technical performance.

Stocks To Watch: Legend Biotech Corp Sees RS Rating Rise To 83
14 Jul, 2021 FinancialContent

Legend Biotech Corp sees its Relative Strength Rating enter the 80-plus level.

Legend Biotech Corporation (LEGN) is a NASDAQ Common Stock listed in , ,

970x250